Oncology & Hematology Clinical Trial Experience

A deep bench of knowledge that pairs oncology development expertise with wide-ranging rare disease experience in the largest areas of unmet need, including new treatments in cell and gene therapies and immuno-oncology.

The tireless pursuit of novel oncology treatments

The new course of cancer therapy

Precision medicine – devising patient-specific treatments to combat diseases once considered incurable – is radically changing the way the world looks at cancer therapy. The leaders in this field are small biotech and specialty pharmaceutical companies – organizations sometimes no larger than a few people and a single molecule. Our clinical trial expertise helps you get from brilliant idea to life-changing reality.

Why choose Premier?

More than 310 hematology and oncology projects completed in the past five years, including multiple rare cancer and cell and gene therapy studies
Expertise ranging from small dose-finding studies to large multinational trials
Every aspect, from trial design and investigators to sites and patient selection, customized for your indication – including preferential regulatory pathways and other strategies for successful early planning and engagement

PREMIER PERSPECTIVE

Tumor-agnostic treatments

The grouping of cancer based on molecular subtypes has changed not only how cancer is categorized but also how novel therapies are investigated in clinical trials. In this blog post, we explore the changing rare oncology landscape and novel approaches to rare cancer trials.

Adaptive trial designs

With the emergence of precision medicine, we are seeing a shift in how early-phase oncology trials are conducted, including a growing number of Phase 1 trials reporting preliminary response rates. This shift is due in part to an increase in adaptive trial designs.

download